Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
The Effect of the Bisphosphonate Ibandronate on Breast Cancer Metastasis to Visceral Organs
Authors
Toshimi Michigami
Toru Hiraga
Paul J. Williams
Maria Niewolna
Riko Nishimura
Gregory R. Mundy
Toshiyuki Yoneda
Publication date
01-10-2002
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2002
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1019905111666

Other articles of this Issue 3/2002

Breast Cancer Research and Treatment 3/2002 Go to the issue

Subject Index

Subject index, Volume 75

OriginalPaper

Reducing Disparities in Breast Cancer Survival: A Columbia University and Avon Breast Cancer Research and Care Network Symposium*

OriginalPaper

Microcysts and Breast Cancer: A Study of Biological Markers in Archival Biopsy Material

OriginalPaper

Patterns of Aneusomy for Three Chromosomes in Individual Cells from Breast Cancer Tumors

OriginalPaper

Origin and Progression of Pregnancy-Dependent Mammary Tumors Induced by New Mouse Mammary Tumor Virus Variants

Instructions for Authors

Instructions for Authors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits